Most CNS failures are predictable.

Preclinical data that won't replicate.

Trial designs that can't bridge the species gap.

Phase II signals that were never adequately powered — mistaken for efficacy, then exposed at Phase III scale.

The warning signs are visible earlier than most teams realize, and long before the losses become unavoidable.

Thirty years of experience in translational neuroscience research has taught us exactly where the translation breaks down. Our assessments are led by a physician-scientist with doctoral training in chemical neurotransmission, multinational research leadership in neuroscience, and direct consulting experience spanning compound selection, program strategy, and platform development - integrated with AI-assisted literature synthesis and biomarker pattern analysis.

Our independent assessments identify the critical gaps between laboratory promise and clinical reality - helping investors make informed decisions and companies strengthen their scientific evidence before it costs either of them.